瑞舒伐他汀联合羟考酮缓释片治疗晚期非小细胞肺癌的临床疗效及对患者血清IL-6、TNF-α的影响

摘要

Objective To explore the clinical efficacy of rosuvastatin combined with oxycodone sustained release tablets in patients with advanced non-small cell lung cancer and its effects on serum IL-6 and TNF-αlevels.Methods 62 cases with advanced non-small cell lung cancer from May 2014 to May 2016were divided into observation group and control group according to random number table, each group with 31 cases.Control group were treated with oxycodone sustained-release tablets, and observation group were treated with rosuvastatin and oxycodone sustained-release tablets.The levels of serum IL-6 and TNF-αwere compared pre-and post-treatment betweene two groups.The effective dose, the number of painful pain, the NRS score, the improvement of quality of life of oxycodone hydrochloride sustained-release tablets after treatment and adverse reaction rate were observed. Results After treatment, serum IL-6, TNF-αlevels in two groups were significantly lower than pre-treatment (P <0.05), and which in observation group were significantly lower than control group (P<0.05).Compared with control group, the effective dose of Oxycodone Hydrochloride Prolonged-release Tablets, broke out pain, NRS score in observation group were significantly higher ( P <0.05 ) .The effective rate of cancer pain treatment in observation group was 96.77% (30/31), significantly higher than 74.19% (23/31) of control group (χ2 =12.269, P<0.0001).The improvement of quality of life incontrol group was 32.25%, significantly lower than 80.64% in observation group (P<0.05).There was no significant difference in adverse reactions between two groups.Conclusion Rosuvastatin combined with oxycodone sustained release tablets in treatment with advanced non-small cell lung cancer were effective, and can reduce the patient's serum IL-6, TNF-αlevels effectively.%目的 探讨瑞舒伐他汀联合羟考酮缓释片治疗晚期非小细胞肺癌的临床疗效及对患者血清IL-6、TNF-α的影响.方法选择温州医科大学附属第一医院2014年2月~2016年2月收治的晚期非小细胞肺癌患者62例,采用系统随机的方法分为对照组和观察组,每组各31例.对照组采用羟考酮缓释片进行治疗,观察组采用瑞舒伐他汀联合羟考酮缓释片进行治疗.比较2组患者治疗前后血清IL-6、TNF-α水平,观察2组患者治疗后的盐酸羟考酮缓释片有效剂量、爆发疼痛次数、NRS评分、生活质量改善情况及不良反应发生情况.结果治疗后,2组患者血清IL-6、TNF-α水平均较治疗前显著降低(P<0.05),且观察组患者血清IL-6、TNF-α显著低于对照组(P<0.05).观察组患者的盐酸羟考酮缓释片有效剂量、爆发疼痛次数、NRS评分明显低于对照组(P<0.05).观察组患者癌痛治疗有效率为96.77%(30/31),明显高于对照组患者的74.19%(23/31),组间比较差异有统计学意义(χ2=12.269,P<0.05).治疗后,对照组患者的生活质量的改善有效率为32.25%,明显较低观察组患者的80.64%(P<0.05).2组患者不良反应发生率差异无统计学意义.结论采用瑞舒伐他汀联合羟考酮缓释片治疗晚期非小细胞肺癌患者有较好的疗效,且能有效降低患者血清IL-6、TNF-α水平.